Infection
Positive results with new oral microbiome drug for C. diff
Finch Therapeutics announced positive topline results from a randomized controlled trial of CP101 for the prevention of recurrent Clostridioides difficile infection, according to a press release.
Steroid use increases COVID-19 hospitalization risk for patients with rheumatic diseases
Moderate to high glucocorticoid use, defined as 10 mg per day or more, is associated with a greater risk for hospitalization for COVID-19 among patients with rheumatic disease, according to data published in Annals of the Rheumatic Diseases.
Texas Children’s Hospital ranked No. 1 for pediatric cardiology and heart surgery
Texas Children’s Hospital achieved the No. 1 rank on U.S. News & World Report’s list of best hospitals for pediatric cardiology and heart surgery for the fourth consecutive year.
Clinical distancing of patients with advanced HF, transplant may protect against COVID-19
One hospital system protected its patients with advanced HF and cardiac transplant from COVID-19 by safely moving them from a central hospital, which was redesigned to care for patients with COVID-19, to a cardiac specialty hospital with no patients with COVID-19, according to a paper published in The Journal of Heart and Lung Transplantation.
Real-world FMT seen as highly effective for C. diff treatment
Subcutaneous ICD noninferior to transvenous ICD for primary, secondary prevention
A subcutaneous implantable cardioverter defibrillator was noninferior to a transvenous ICD regarding major ICD-related adverse events in patients indicated for such treatment, according to data from the PRAETORIAN trial presented at the virtual Heart Rhythm Society Annual Scientific Sessions.
Reused, resterilized implantable cardiac devices show similar 2-year outcomes as new
Pacemakers or implanted cardiac defibrillators that were retrieved postmortem, resterilized and reused in underserved countries conferred similar rates of infection and device-related deaths as new devices implanted in Canada.
Durvalumab feasible, safe for HIV-1-infected patients with cancer
Durvalumab appeared feasible and safe for patients with cancer and HIV-1 infection who receive combination antiretroviral therapy, according to results of a single-arm phase 2 study published in JAMA Oncology.
PE twice as prevalent in COVID-19 in case series report
A case series published in Circulation by physicians at Lille University Hospital in France reported twice the prevalence of pulmonary embolism among patients with COVID-19 admitted to the ICU compared with patients admitted to the ICU the same time in 2019.